|Bid||0.00 x 1300|
|Ask||0.00 x 1800|
|Day's Range||25.83 - 27.03|
|52 Week Range||21.27 - 35.48|
|Beta (3Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.67|
DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018, in New York City. Theravance Biopharma management and R&D teams will provide an overview of the Company's research and development strategy, plus clinical programs and emerging research projects in therapeutic areas such as inflammatory intestinal diseases, autonomic disorders, severe asthma, lung transplant rejection, idiopathic pulmonary fibrosis, and diabetic macular edema.
DUBLIN, Dec. 3, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company") today announced the closing of a private placement of $250 million of non-recourse PhaRMASM 9% fixed rate term notes. The notes are secured by a portion of the future payments the Company expects to receive related to royalties due on net sales of Trelegy Ellipta. The Company intends to use the net proceeds from this transaction to support continued execution of its key strategic programs.
Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
DUBLIN, Nov. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-8236, a novel, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor which has demonstrated potency in preclinical assessments. The Company is developing TD-8236 as an investigational compound with the potential to treat a range of serious respiratory diseases. TD-8236 is an internally-discovered JAK inhibitor that has demonstrated a high affinity and selectivity for each of the JAK family enzymes (JAK1, JAK2, JAK3 and TYK2).
Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.
DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administered and gut-selective pan-Janus kinase (JAK) inhibitor in development as a treatment for multiple inflammatory intestinal diseases.
The conference will be held November 27 - 29 at the Boston Harbor Hotel. The conference will be held November 27 - 29 at the Lotte New York Palace Hotel. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab.
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Our weekly guide to what's happening in the biotech, medical devices, diagnostics and hospital space.
DUBLIN, Nov. 12, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the European Commission authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognizing the product's effect on exacerbations and making it the first single-inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva (formerly Theravance, Inc.).
DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year.
Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems. The treatment, Yupelri https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf, ...
Short interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.
DUBLIN, Nov. 7, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that management will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018, at 8:35 a.m. MST. The conference will be held from November 12 - 15 at the Phoenician in Scottsdale, AZ. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Theravance Bio (TBPH) delivered earnings and revenue surprises of 6.78% and 21.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the George Town, Cayman Islands-based company said it had a loss of $1.10. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...